Modeling long-term health and economic implications of new treatment strategies for Parkinson's disease: an individual patient simulation study. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Chandler, Conor; Folse, Henri; Gal, Peter; Chavan, Ameya; Proskorovsky, Irina; Franco-Villalobos, Conrado; Yang, Yunyang; Ward, Alex
• Is Part Of: Journal of market access & health policy. Volume 9:Issue 1(2021)
• Publication Date: 2021-01-01
• Subjects: Anti-Parkinson therapy -- cost-effectiveness -- cost-utility -- economic model -- Parkinson's disease; Medical policy -- Periodicals; Medical policy -- Economic aspects -- Periodicals; International trade -- Environmental aspects -- Periodicals; Health Policy -- economics; Technology Assessment, Biomedical; Marketing of Health Services; International trade -- Environmental aspects; Medical policy; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 362.1
• DOI: 10.1080/20016689.2021.1922163
• Languages: English
• ISSNs: 2001-6689

Abstract

ABSTRACT: Background : Simulation modeling facilitates the estimation of long-term health and economic outcomes to inform healthcare decision-making. Objective : To develop a framework to simulate progression of Parkinson's disease (PD), capturing motor and non-motor symptoms, clinical outcomes, and associated costs over a lifetime. Methods : A patient-level simulation was implemented accounting for individual variability and interrelated changes in common disease progression scales. Predictive equations were developed to model progression for newly diagnosed patients and were combined with additional sources to inform long-term progression. Analyses compared a hypothetical disease-modifying therapy (DMT) with a standard of care to explore the drivers of cost-effectiveness. Results : The equations captured the dependence between the various measures, leveraging prior values and rates of change to obtain realistic predictions. The simulation was built upon several interrelated equations, validated by comparison with observed values for the Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) and UPDRS subscales over time. In a case study, disease progression rates, patient utilities, and direct non-medical costs were drivers of cost-effectiveness. Conclusions : The developed equations supported the simulation of early PD. This model can support conducting simulations to inform internal decision-making, trial design, and strategic planning early in the development of new DMTs entering clinical trials.